New image and new editorial organization in Revista de la Sociedad del Dolor
Rev. Soc. Esp. Dolor. 2019; 26(1): 1-1 / DOI: 10.20986/resed.2019.3728/2019
Avances en Dolor
Micro RNAs: A new way for the management of neuropathic pain?
Rev. Soc. Esp. Dolor. 2019; 26(1): 2-3 / DOI: 10.20986/resed.2019.3730/2019
Enrique J. Cobos del Moral
The use of opioids in older adults
Rev. Soc. Esp. Dolor. 2019; 26(1): 4-5 / DOI: 10.20986/resed.2019.3731/2019
Inmaculada Failde Martínez
Effects of multimodal treatment in patients with complex regional pain syndrome type 1 with, at least, 6 months of evolution: a descriptive study
Rev. Soc. Esp. Dolor. 2019; 26(1): 6-13 / DOI: 10.20986/resed.2018.3651/2018
Andrea Daniela Tabach Apraiz, María Lorena Oyanadel Maldonado, Hector Gutierrez Espinoza, Daniel Bueno Buker
Objectives: The main objective of this work is to describe the changes in pain after a multimodal treatment scheme in patients with Complex Regional Pain Syndrome type 1 (CRPS 1), with more than 6 months of evolution, who enter treatment at the Physical Medicine and Rehabilitation Service of the San Borja Arriarán Clinical Hospital.
Material and method: Series of cases of patients...
Dexmedetomidine versus endovenous lidocaine in breakthrough pain control and functionality in patients with lumbar stenosis
Rev. Soc. Esp. Dolor. 2019; 26(1): 14-20 / DOI: 10.20986/resed.2018.3656/2018
Nayely Teresa Guillén Ramírez, Miguel Jimenez Olvera, Marcos Antonio Morales Aguila, Carlos Omar López López, Arturo Reding-Bernal, Juan Carlos Arista Villanueva, Rafael Orlando Vallejo Estrella, David Javier Amado Magdaleno, Patricia Badillo Rivero
Introduction: The pain is a reason for absenteeism labour, especially breakthrough pain secondary to narrow lumbar canal. Dexmedetomidine is an analgesic, act by inhibiting the release of substance P in the nociceptive pathway and blocks the aspartate and glutamate receptors. On the other hand, lidocaine also prevents and relieves pain by interrupting neuroconduction, binding
Psychosocial factors in chronic cancer pain: a Delphi study
Rev. Soc. Esp. Dolor. 2019; 26(1): 21-30 / DOI: 10.20986/resed.2018.3658/2018
Sònia Expósito-Vizcaíno, Dolors Burjalés-Martí, Jordi Miró
Background and objectives: Chronic cancer pain is a complex experience that results from the interaction of multiple factors. Identifying which factors play an important role in shaping this experience would reduce its effects. The main objective of this study was to identify which factors are related to the chronifi cation of cancer pain, in the opinion of a group of experts. And...
Project adapta: adequacy of treatment in breakthrough cancer pain
Rev. Soc. Esp. Dolor. 2019; 26(1): 31-43 / DOI: 10.20986/resed.2018.3661/2018
Cecilio Alamo Gonzalez, Luis Cabezón Gutiérrez, Grupo de trabajo Proyecto ADAPTA
Introduction: Transmucosal fentanyl has specific properties which make it ideal for the treatment of breakthrough cancer pain (BTCP). Although there is a broad consensus for the administration of transmucosal fentanyl for BTCP in Spain, there is uncertainty as to the way oncologists adjust their prescription to the patient and what are the determinants of the choice of different pharmaceutical...
Influence of psychosocial factors in the experience of musculoskeletal pain: a literatura review
Rev. Soc. Esp. Dolor. 2019; 26(1): 44-51 / DOI: 10.20986/resed.2018.3679/2018
Felipe Araya Quintanilla, Iván Alejandro Cuyul Vásquez
Musculoskeletal pain is a health problem that affects approximately 33 % of the adult population,
of which 56 % corresponds to elderly people and 35% to people of working age. Some epidemiological investigations have shown that there are certain groups of people within the population most likely to develop chronic musculoskeletal pain, these studies have allowed to identify different...
Letter to the Editor
Do our patients need opioids and benzodiazepines concurrently?
Rev. Soc. Esp. Dolor. 2019; 26(1): 59-60 / DOI: 10.20986/resed.2017.3552/2016
Antonio Alcántara Montero, Adoración González Curado
New indication of capsaicin 8 % patch: painful diabetic peripheral neuropathy
Rev. Soc. Esp. Dolor. 2019; 26(1): 60-61 / DOI: 10.20986/resed.2017.3556/2016
Antonio Alcántara Montero, Adoración González Curado
Fibromyalgia and cortical reorganization. What does the evidence say?
Rev. Soc. Esp. Dolor. 2019; 26(1): 61-62 / DOI: 10.20986/resed.2017.3595/2017
Felipe Araya Quintanilla, Maria Jesus Muñoz Yañez
In response to the article "Radio frequency thermal and splanchics nerves block. A case report"
Rev. Soc. Esp. Dolor. 2019; 26(1): 62-63 / DOI: 10.20986/resed.2019.3714/2018
Maria luisa Franco Gay
Oxytocin and chronic pain in humans
Rev. Soc. Esp. Dolor. 2019; 26(1): 52-58 / DOI: 10.20986/resed.2018.3664/2018
Ximena Palacios Espinosa, Ana María Gómez Carvajal, Juan Sebastián Botero Meneses, Leonardo Palacios Sánchez
Oxytocin (OT) is a long known neuropeptide, and it's uses in clinical practice, mainly those regarding obstetrics have been thoroughly studied. However, there's been an increasing interest in identifying other roles OT plays in emotion, cognition, perception and higher cognitive processing. OT is also believed o have a mayor role in the physiology and physiopathology of pain. We have...